F. Bustin

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Roy S. Herbst, Rafat Ansari, F. Bustin et al. · The Lancet · 2011 · 391 citations · Full text

Oncology, Erlotinib Versus Erlotinib, Medicine +7

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

Robert C. Doebele, David R. Spigel, Mustapha Tehfé et al. · Cancer · 2014 · 84 citations

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

Cesare Gridelli, Filippo de Marinis, Michael Thomas et al. · Journal of Thoracic Oncology · 2014 · 53 citations · Full text

Aging, Geriatrics, Patient Safety +5

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

Mary O’Brien, Krzystof Konopa, Paul Lorigan et al. · European Journal of Cancer · 2011 · 29 citations

Oncology, Single Agent, Medicine +8